| Net Loss Per Share |
3. Net Loss Per Share
The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2012 |
|
2011 |
|
2010 |
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations |
|
$ |
(72,624 |
) |
$ |
(64,852 |
) |
$ |
(56,411 |
) |
|
Net income from discontinued operations |
|
|
— |
|
|
— |
|
|
4,551 |
|
|
Less: Net income from discontinued operations attributable to noncontrolling interest |
|
|
— |
|
|
— |
|
|
(1,121 |
) |
| |
|
|
|
|
|
|
|
|
Net income from discontinued operations attributable to Ironwood Pharmaceuticals, Inc. |
|
|
— |
|
|
— |
|
|
3,430 |
|
| |
|
|
|
|
|
|
|
|
Net loss attributable to Ironwood Pharmaceuticals, Inc. |
|
$ |
(72,624 |
) |
$ |
(64,852 |
) |
$ |
(52,981 |
) |
| |
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares used in net loss per share attributable to Ironwood Pharmaceuticals, Inc.—basic and diluted |
|
|
106,402,639 |
|
|
99,874,790 |
|
|
89,653,364 |
|
| |
|
|
|
|
|
|
|
|
Net loss per share associated with continuing operations—basic and diluted |
|
$ |
(0.68 |
) |
$ |
(0.65 |
) |
$ |
(0.63 |
) |
|
Net income per share from discontinued operations attributable to Ironwood Pharmaceuticals, Inc.—basic and diluted |
|
|
— |
|
|
— |
|
|
0.04 |
|
| |
|
|
|
|
|
|
|
|
Net loss per share attributable to Ironwood Pharmaceuticals, Inc.—basic and diluted |
|
$ |
(0.68 |
) |
$ |
(0.65 |
) |
$ |
(0.59 |
) |
| |
|
|
|
|
|
|
|
The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2012, 2011 and 2010 as they would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2012 |
|
2011 |
|
2010 |
|
|
Options to purchase common stock |
|
|
19,539,429 |
|
|
16,424,500 |
|
|
14,603,229 |
|
|
Shares subject to repurchase |
|
|
80,230 |
|
|
160,413 |
|
|
284,960 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
19,619,659 |
|
|
16,584,913 |
|
|
14,888,189 |
|
| |
|
|
|
|
|
|
|
The number of shares issuable under the Company's employee stock purchase plan that were excluded from the calculation of diluted weighted average shares outstanding because their effects would be anti-dilutive was insignificant.
|